Skip to main content
search

About Us

BRIM Biotechnology: bringing transformational treatments to patients sooner

Milestones

Our corporate milestones

World-leading expertise in translational science has enabled BRIM to rapidly advance several discoveries into the clinic and successfully spin out Ascendo Biotechnology, Inc in 2019.

Our stem cell regenerative Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) platform underpins several products in our pipeline and has the potential to be effective in multiple therapy areas and indications.

 
2024
  • Plan to submit IPO application.
2023
  • Initiated BRM421 Phase III clinical trial in the US.
  • Series F financing (USD 48M).
  • Approval letter from the Ministry of Economic Affairs (MOEA) on being recognized as a Technology-based Enterprise.
  • Submitted BRM424 Phase II clinical trial application to the US FDA.
  • On December 8, 2023, received the Application Procedure and Forms for Letter of Opinion by MOEA on Technology-based Enterprise or Cultural and Creative Enterprise with Marketability. BRIM Biotechnology will proceed with the stock listing application as scheduled.
2022
  • Series E financing (USD 20M).
  • Approved for the initial public offering by the Taipei Exchange in January.
  • Approved by the Taipei Exchange to trade on the Emerging Stock Board (ESB) from June 23.
  • Strategic collaboration with Ora, Inc. for Phase III clinical trials.
  • Completed BRM421 US FDA End-of-Phase 2 (EOP2) meeting.
2021
  • Conducted two FDA TYPE C meetings for BRM421.
  • Series D financing (USD 11M).
  • Applied for US FDA orphan drug designation for BRM424.
  • Approved by the Industrial Development Bureau, Ministry of Economic Affairs as a biotech new drug company from 2016 to 2021. Obtaining new drug designations for BRM421, BRM132, BRM423, and BRM521.
2020
  • Completed the second human clinical trial (Phases II and III) for BRM421 in the US.
  • Won the Taipei Biotech Awards “Gold Medal for Innovation Award”.
  • Awarded the Taiwan Bio Awards “2020 Emerging Company of the Year” by the Taiwan Bio Industry Organization (Taiwan BIO).
2019
  • Established Ascendo Biotechnology, Inc. (ASCENBIO) and raised USD 12M.
  • Signed an agreement with Grand Pharmaceutical Group Limited granting exclusive rights to develop and commercialize the dry eye disease in China, Hong Kong, and Macau.
  • Completed formulation optimization for BRM421 and submitted the US FDA Phase II/III clinical trial application.
  • Won the 16th National Innovation Award.
  • Awarded the Taipei Prominent Enterprise Award.
2018
  • Series C financing (USD 6M).
  • Presented BRM421 Phase II clinical data at the American Academy of Ophthalmolog (AAO) Annual Meeting.
  • Won the “Silver Award for Drug Technology Research and Development” from the Taiwan FDA National Pharmaceutical Technology & Research Development Award (NPRDA).
2017
  • Completed the first human clinical trial (Phase II) for BRM421 in the US.
  • Received US FDA IND approval for BRM132.
2016
  • Completed preclinical development for BRM421 and submitted the US FDA IND application.
  • Launched early development projects (BRM141 and BRM25X) in collaboration with domestic academic and research institutions.
2015
  • Series B financing (USD 26M).
  • Licensed Pigment derived Short Peptide (PDSP) platform from Mackay Memorial Hospital.
2014
  • Series A financing (USD 4M).
  • In-licensed BRM132.
Close Menu